Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
Open accessThe DOI matches its Crossref record; 28 of the 47 references it cites were found in a registry or an index.
Abstract
Background: The sodium-glucose co-transporter 2 inhibitor dapagliflozin decreases haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin:creatinine ratio (UACR) in patients with type 2 diabetes. The efficacy and safety of this drug have not been properly defined in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease (CKD). Methods: In a pooled analysis of 11 phase 3 randomized controlled clinical trials, we determined least square mean changes in HbA1c, body weight, BP, estimated glomerular filtration rate (eGFR) and UACR over 102 weeks in patients with type 2 diabetes and an eGFR between 12 to less than 45 mL/min/1.73 m2 receiving placebo (n = 69) or dapagliflozin 5 or 10 mg (n = 151). Effects on UACR were determined in a subgroup of patients with baseline UACR ≥30 mg/g (n = 136). Results: Placebo-corrected changes in HbA1c with dapagliflozin 5 and 10 mg were 0.03% [95% confidence interval (CI) -0.3-0.3] and 0.03% (95% CI -0.2-0.3) during the overall 102-week period. Dapagliflozin 5 and 10 mg compared with placebo reduced UACR by - 47.1% (95% CI -64.8 to - 20.6) and -38.4% (95% CI -57.6 to - 10.3), respectively. Additionally, dapagliflozin 5 and 10 mg compared with placebo reduced BP and body weight. eGFR increased with placebo during the first 4 weeks but did not change with dapagliflozin. There were no between-group differences in eGFR at the end of follow-up. Adverse events associated with renal function occurred more frequently in the dapagliflozin 10-mg group. These events were mainly asymptomatic increases in serum creatinine. Conclusions: Dapagliflozin did not decrease HbA1c in patients with type 2 diabetes and Stages 3b-4 CKD, but decreased UACR, BP and body weight to a clinically meaningful extent. These results support a large outcome trial in this population to confirm long-term safety and efficacy in reducing adverse clinical endpoints.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite their effects on intravascular volume, BP lowering with SGLT2 inhibitors is not accompanied by a compensatory increase in heart rate.29”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 2×
“In addition, randomized placebo-controlled trial data also indicate that the risk of acute kidney injury (AKI) is not increased during SGLT2 inhibition [5, 26].”
BackgroundHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376 · cited 1×
“in the S1 segment of the proximal tubule, thereby augmenting urinary glucose and sodium excretion [3].”
BackgroundSelf-citationKidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298 · cited 1×
“Both diabetes and CKD account for an increased risk of premature mortality, cardiovascular morbidity and end-stage kidney failure [2].”
BackgroundBailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 860
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
Glomerular hyperfiltration: definitions, mechanisms and clinical implications
Helal, I., Fick-Brosnahan, G. M., Reed-Gitomer, B., & Schrier, R. W. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.19 · Cited by 673 · cited 1×
“In many primary and secondary kidney diseases, for example, focal segmental glomerulosclerosis, immunoglobulin A (IgA) nephropathy, hypertensive nephrosclerosis and obesity-induced nephropathy, maladaptive functional renal hemodynamic changes are thought to occur, including increases in renal blood flow, GFR and filtr…”
BackgroundKohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574 · cited 4×
“The previous studies including patients with Stage 3 CKD and a small group of patients with Stage 4 CKD produced similar reductions in UACR, BP and body weight, but during a shorter follow-up period [6, 8].”
BackgroundMethodResultInfluentialBolinder, J., Ljunggren, Ö., Johansson, L., Wilding, J., Langkilde, A. M., Sjöström, C. D., Sugg, J., & Parikh, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12189 · Cited by 482 · cited 1×
“It has been speculated that this increase in phosphate may precipitate fractures, but recent data with dapagliflozin in patients with type 2 diabetes indicate no increased fracture risk or increased rate of bone turnover as assessed by biomarkers [15, 29, 30].”
ResultSelf-citationWilding, J. P. H., Woo, V., Soler, N. G., Pahor, A., Sugg, J., Rohwedder, K., Parikh, S., & for the Dapagliflozin 006 Study Group* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-6-201203200-00003 · Cited by 467
Rosenstock, J., Vico, M., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 408
Strojek, K., Yoon, K. H., Hruba, V., Elze, M., Langkilde, A. M., & Parikh, S. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01434.x · Cited by 406
Cherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383 · cited 1×
“This finding is in line with previous studies with dapagliflozin and empagliflozin [4, 31].”
ResultHenry, R. R., Murray, A. V., Marmolejo, M. H., Hennicken, D., Ptaszynska, A., & List, J. F. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.02911.x · Cited by 310
Jabbour, S. A., Hardy, E., Sugg, J., Parikh, & for the Study 10 Group (2014) · Diabetes Care · doi:10.2337/dc13-0467 · Cited by 286
Yale, J. ‐., Bakris, G., Cariou, B., Nieto, J., David‐Neto, E., Yue, D., Wajs, E., Figueroa, K., Jiang, J., Law, G., et al. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12348 · Cited by 273 · cited 3×
“The previous studies including patients with Stage 3 CKD and a small group of patients with Stage 4 CKD produced similar reductions in UACR, BP and body weight, but during a shorter follow-up period [6, 8].”
BackgroundMethodResultBailey, R. A., Wang, Y., Zhu, V., & Rupnow, M. F. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-415 · Cited by 247 · cited 1×
“Approximately 30–40% of all patients with diabetes also have chronic kidney disease (CKD) [1].”
BackgroundDrug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis
Lambers Heerspink, H. J., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070688 · Cited by 242 · cited 1×
“The magnitude of albuminuria reduction was clinically meaningful and, based on large epidemiological studies, might be expected to translate into an 40% relative risk reduction for end-stage kidney disease [24].”
BackgroundHeerspink, H. J. L., Johnsson, E., Gause‐Nilsson, I., Cain, V. A., & Sjöström, C. D. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12654 · Cited by 191 · cited 2×
“The GFR decline is completely reversible after drug discontinuation [4, 5].”
BackgroundResultSelf-citationAcute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis
Nadkarni, G. N., Ferrandino, R., Chang, A., Surapaneni, A., Chauhan, K., Poojary, P., Saha, A., Ferket, B., Grams, M. E., & Coca, S. G. (2017) · Diabetes Care · doi:10.2337/dc17-1011 · Cited by 188 · cited 5×
“In addition, randomized placebo-controlled trial data also indicate that the risk of acute kidney injury (AKI) is not increased during SGLT2 inhibition [5, 26].”
BackgroundInfluentialLeiter, L. A., Cefalu, W. T., de Bruin, T. W. A., Gause‐Nilsson, I., Sugg, J., & Parikh, S. J. (2014) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12881 · Cited by 182
Cefalu, W. T., Leiter, L. A., de Bruin, T. W. A., Gause-Nilsson, I., Sugg, J., & Parikh, S. J. (2015) · Diabetes Care · doi:10.2337/dc14-0315 · Cited by 182
Edelman, S. V. (1998) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70019-5 · Cited by 77 · cited 1×
“Improving glycemic control has been proven to be important in reducing the risk of microvascular complications of diabetes [19].”
BackgroundVlotides, G., & Mertens, P. R. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu299 · Cited by 44
Blevins, T. C., & Farooki, A. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1256747 · Cited by 38 · cited 1×
“It has been speculated that this increase in phosphate may precipitate fractures, but recent data with dapagliflozin in patients with type 2 diabetes indicate no increased fracture risk or increased rate of bone turnover as assessed by biomarkers [15, 29, 30].”
ResultEffects of Incretin-Based Therapies and SGLT2 Inhibitors on Skeletal Health
Egger, A., KRAENZLIN, M. E., & Meier, C. (2016) · Current Osteoporosis Reports · doi:10.1007/s11914-016-0337-9 · Cited by 26 · cited 1×
“It has been speculated that this increase in phosphate may precipitate fractures, but recent data with dapagliflozin in patients with type 2 diabetes indicate no increased fracture risk or increased rate of bone turnover as assessed by biomarkers [15, 29, 30].”
ResultDrug-induced reduction in albuminuria is associated with subsequent renoprotection: A meta-analysis
Heerspink, H. J. L., Kröpelin, T. F., Hoekman, J., & de Zeeuw, D. (2015) · Utrecht University Repository (Utrecht University) · Cited by 13
Self-citation
Cited by
KDIGO 2020 Clinical practice guideline for diabetes management in chronic kidney disease
de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.019 · Cited by 1,399
Self-citationKDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
Self-citationToyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
Self-citationKraus, B. J., Weir, M. R., Bakris, G. L., Mattheus, M., Cherney, D. Z. I., Sattar, N., Heerspink, H. J. L., Ritter, I., von Eynatten, M., Zinman, B., et al. (2021) · Kidney International · doi:10.1016/j.kint.2020.10.031 · Cited by 219
Self-citationHeerspink, H. J. L., Stefansson, B. V., Chertow, G. M., Correa-Rotter, R., Greene, T., Hou, F.-F., Lindberg, M., McMurray, J., Rossing, P., Toto, R., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz290 · Cited by 218
Self-citation
Metadata
- Authors
- Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L.
- Affiliations
- University Medical Center Groningen (NL)
- University College London (GB)
- AstraZeneca (Sweden) (SE)
- Department of Cardiovascular and metabolic diseases, Global Medicines Development, AstraZeneca, Gothenburg, Sweden
- Department of Biometrics and Information Sciences, Bogier Clinical and IT Solutions, Raleigh, NC, USA
- Corresponding author
- Heerspink, Hiddo J L
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01-23
- Volume
- 33
- Issue
- 11
- Pages
- 2005-2011
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC6212718
- OpenAlex
- W2794310633
- Cited by
- 102
- References
- 47
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 7 · 2023: 10 · 2022: 15 · 2021: 12 · 2020: 21 · 2019: 15 · 2018: 15
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nephrology Dialysis Transplantation (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, chronic kidney disease, albuminuria, urinary albumin-creatinine ratio, estimated glomerular filtration rate, glycemic control, blood pressure, body weight, serum creatinine, drug safety, renal function, adverse events, dose comparison
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Adult, Aged, Albuminuria, Benzhydryl Compounds, Blood Pressure, Body Weight, Creatinine, Diabetes Mellitus, Type 2, Female, Glomerular Filtration Rate, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Randomized Controlled Trials as Topic, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.